BioWorld

April 26, 2004

Stock Winners and Losers For The Week

Biotech-Big Pharma Collaborations: New Agreements, Feb. 20 - April 21, 2004#

Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: Feb. 20 - April 21, 2004#

Biotech-Big Pharma Collaborations: Modified And Terminated Agreements, Feb. 20 - April 21, 2004#

BioWorld Stock Report For Public Biotechnology Companies

Visionary Eyetech Saw Aptamers' Value, Turned Macugen Into Gold

Eyetech Pharmaceuticals Inc.'s CEO David Guyer typically is humble when he talks about the company's landmark potential $750 million deal in late 2002 with Pfizer Inc. for Macugen, the in-licensed aptamer for age-related macular degeneration. Read More

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...